About Us
- News and Announcements
- Newsletter
- Our Team
- Publications
- Support Our Work
- Contact Us
Our Center News
__________________________________________________________________________________________________________
UCSD Center of Excellence completes the KINECT-HD2 Neurocrine Study
We are thrilled to announce the successful completion of our Neurocrine KINECT-HD2 study, which investigated the efficacy of Valbenazine in reducing chorea associated with Huntington's disease. Thanks to the dedication of our participants, the study yielded positive results, and Valbenazine has now been approved by the FDA for use in Huntington's patients! This marks an important milestone in improving the quality of life for those affected by HD. We extend our heartfelt gratitude to everyone who contributed to this success. If you are interested in learning more about Valbenazine and its use in managing HD symptoms, please reach out to our site today!UCSD Named Center of Excellence
UC San Diego is one of 56 centers nationwide, and 11 partner sites, to receive the prestigious designation of Center of Excellence by the Huntington's Disease Society of America, which recognizes centers for their elite multidisciplinary approach to Huntington’s disease care and research. This is the 20th consecutive year that UCSD has earned the HDSA Center of Excellence designation.
The HDCRC is on Social Media!
UCSD Huntington's Disease Clinical Research Center is on Twitter! We are entering a new phase here at the HDCRC that will enable us to engage more with the HD Community! Be on the lookout for new social media updates. And don't forget to join our mailing list to receive updates directly to your inbox!